Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

NCT ID: NCT02114333

Last Updated: 2020-07-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 160 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-05-31
• Study Completion Date: 2020-05-31

Brief Summary

This study will compare the two vaccines that have been developed to prevent and/or lessen the effects of shingles. One vaccine is live (Zostavax, licensed by FDA) and the other, herpes zoster subunit (HZ/su), contains a piece of the shingles virus (not live) and an ingredient that may enhance the body's immune response to the vaccine, and is currently investigational. The vaccines are being compared to assess their ability to stimulated protection against shingles. The study will provide an opportunity to determine the safety profile of each vaccine in a single trial. The study will also look at the effect of age on the immune response to the two vaccines and on the persistence of these responses.

Detailed Description

160 people from the Denver area will participate. Duration is up to 5 years with 10-12 visits in that period. Subjects are randomized into one of 4 arms to receive either Zostavax or HZ/su. In this single blind study all subjects receive 2 injections: one at the first visit (Day 0) and the second at Day 60. HZ/su subjects will receive vaccine at both visits; Zostavax subjects will receive vaccine at the first visit and a placebo at the Day 60 visit. Blood is collected from all subjects at most visits. Some subjects spit into a tube for saliva collection. A urine sample is collected prior to vaccination if subject is a woman of childbearing potential. Subjects are asked to complete a diary to record any reactions in the 30 days after each injection. The Day 90 visit is the last one until the annual visits for blood draws begin at Day 365. Some subjects are also seen at Year 2 and Year 4; all subjects are seen at Year 5 for blood draw.

Conditions

Shingles; Herpes Zoster

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

A - Live zoster vaccine

No previous zoster vaccine; stratified between age groups 50-59 and 70-85

First dose live vaccine, Zostavax (0.65ml, subcutaneous)

Second dose placebo, normal saline (0.65ml. subcutaneous)

Group Type: ACTIVE_COMPARATOR

Zostavax

Intervention Type: BIOLOGICAL

0.65ml, subcutaneous

Placebo

Intervention Type: BIOLOGICAL

0.65ml, subcutaneous

B - recombinant zoster vaccine

No previous zoster vaccine; stratified between age groups 50-59 and 70-85

First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)

Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)

Group Type: ACTIVE_COMPARATOR

HZ/su vaccine

Intervention Type: BIOLOGICAL

0.5ml, intramuscular

C - Live zoster vaccine

One previous dose of zoster vaccine at least 5 years previously, age 70-85

First dose live vaccine, Zostavax (0.65ml, subcutaneous)

Second dose placebo, normal saline (0.65ml. subcutaneous)

Group Type: ACTIVE_COMPARATOR

Zostavax

Intervention Type: BIOLOGICAL

0.65ml, subcutaneous

Placebo

Intervention Type: BIOLOGICAL

0.65ml, subcutaneous

D - recombinant zoster vaccine

One previous dose of zoster vaccine at least 5 years previously, age 70-85

First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)

Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)

Group Type: ACTIVE_COMPARATOR

HZ/su vaccine

Intervention Type: BIOLOGICAL

0.5ml, intramuscular

Interventions

Zostavax

0.65ml, subcutaneous

Intervention Type: BIOLOGICAL

HZ/su vaccine

0.5ml, intramuscular

Intervention Type: BIOLOGICAL

Placebo

0.65ml, subcutaneous

Intervention Type: BIOLOGICAL

Other Intervention Names

Recombinant vaccine; normal saline

Eligibility Criteria

Inclusion Criteria

• History of varicella or residence int he US for 30 years
• For Arms C and D - prior live zoster vaccine at least 5 years previously
• For Arms A and B - Age 50-59 or 70-85
• For Arms C and D - Age 70-85
• For women of childbearing potential, a negative pregnancy test and agreement to use adequate contraception from 30 days before until 3 months after the last dose of any study vaccine

Exclusion Criteria

• History of herpes zoster
• For Arms A and B - prior live zoster vaccine
• Immune compromising illness or therapies or chronic illness
• Allergy to previous herpes zoster vaccine
• Other investigational drugs or vaccines within the past 6 months before the study and until last visit
• Blood products for 3 months prior to or planned during the study
• Concomitant non-topical antiviral therapy within 3 days prior to and 7 days after vaccination.
• Vaccines within 2 weeks (inactive vaccine) or 4 weeks (live vaccine) prior to the study until 30 days after any dose of either vaccine.
• Pregnancy or breast-feeding
• Current drug addiction or alcoholism.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: collaborator

University of Colorado, Denver

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Myron J Levin, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Colorado School of Medicine

Locations

Pediatric Infectious Diseases and Clinical Trials, Universtiy of Colorado School of Medicine

Aurora, Colorado, United States

Countries

United States

References

Johnson MJ, Liu C, Ghosh D, Lang N, Levin MJ, Weinberg A. Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence. J Infect Dis. 2022 Apr 19;225(8):1477-1481. doi: 10.1093/infdis/jiab580.

Reference Type: DERIVED

PMID: 34850039 (View on PubMed)

Weinberg A, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Levin MJ. Comparative Immune Responses to Licensed Herpes Zoster Vaccines. J Infect Dis. 2018 Sep 22;218(suppl_2):S81-S87. doi: 10.1093/infdis/jiy383.

Reference Type: DERIVED

PMID: 30247596 (View on PubMed)

Other Identifiers

13-3192

Identifier Type: -

Identifier Source: org_study_id